942425-69-6 Usage
Uses
Used in Pharmaceutical Research:
TBOC is utilized as a protecting group for amines in peptide synthesis, ensuring the integrity and functionality of the amine groups during the synthesis process. Its high stability and the ability to be easily removed under mild conditions make it an essential component in the production of peptides and other complex organic molecules.
Used in Organic Synthesis:
In the realm of organic synthesis, TBOC is employed to protect amines, facilitating the synthesis of complex organic molecules by preventing unwanted side reactions. Its reliable properties and the ease of removal contribute to the successful synthesis of a wide range of organic compounds.
Used in Drug Development:
TBOC's potential applications extend to the development of new drugs and pharmaceutical compounds. Its versatility and reliability make it a valuable asset in the design and synthesis of novel therapeutic agents, potentially leading to advancements in medicine and healthcare.
Check Digit Verification of cas no
The CAS Registry Mumber 942425-69-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,2,4,2 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 942425-69:
(8*9)+(7*4)+(6*2)+(5*4)+(4*2)+(3*5)+(2*6)+(1*9)=176
176 % 10 = 6
So 942425-69-6 is a valid CAS Registry Number.
942425-69-6Relevant academic research and scientific papers
A modular synthesis of novel 4-amino-7,8-dihydro-1,6-naphthyridin-5(6H)- ones as PDE4 inhibitors
Ferrer, Manel,Roberts, Richard S.,Sevilla, Sara
, p. 4821 - 4825 (2013/09/02)
A versatile, modular synthetic route to a series of 4-amino-7,8-dihydro-1, 6-naphthyridin-5(6H)-ones has been developed. These compounds represent a novel structural class of potent phosphodiesterase IV (PDE4) inhibitors.
LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
-
Page/Page column 64, (2012/05/19)
Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein "A" is S-; -SO-, -SO2-, -O- or NRac-, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined
New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
-
Page/Page column 21; 22, (2011/11/07)
New 7,8-dihydro-1,6-naphthyridin-5(6H)-one derivatives derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).
N-substituted pyrrolopyridinones active as kinase inhibitors
-
Page/Page column 18, (2010/11/27)
Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
